Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Acadia Pharmaceuticals

Start price
Target price
Perf. (%)
€21.86
12.04.22
-
12.04.23
-23.60%
12.04.23

buy
Novocure Ltd

Start price
Target price
Perf. (%)
€64.20
16.03.22
€68.00
16.03.23
-6.99%
17.03.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Nektar Therapeutics

Start price
Target price
Perf. (%)
€2.02
23.01.23
-
23.01.24
-28.00%
03.03.23

Risky Investment
Novocure Ltd

Start price
Target price
Perf. (%)
€68.89
02.01.23
€30.00
31.12.25
71.43%
05.01.23

Could be very worthwhile Investment >20% year
buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€136.00
28.12.21
€142.00
28.12.22
-70.42%
29.12.22

Could be worthwhile Investment >10% per year
Capable Management
Future proof or reliable business model
buy
Opko Health Inc.

Start price
Target price
Perf. (%)
€4.65
28.12.21
-
28.12.22
-75.54%
29.12.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
buy
Sage Therapeutics Inc.

Start price
Target price
Perf. (%)
€37.99
27.12.21
€42.00
27.12.22
-5.05%
28.12.22

Could be worthwhile Investment >10% per year
buy
Neogen Corp.

Start price
Target price
Perf. (%)
€35.40
14.12.21
€38.00
14.12.22
-59.89%
15.12.22

Could be worthwhile Investment >10% per year
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€47.20
07.12.22
-
07.12.23
-16.53%
10.12.22

Risky Investment
buy
Davita Inc.

Start price
Target price
Perf. (%)
€73.02
28.10.22
-
0.45%
28.10.22

Risky Investment
buy
Acceleron Pharma Inc.

Start price
Target price
Perf. (%)
€158.00
28.09.21
-
28.09.22
0.63%
28.09.22

buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€76.50
21.08.22
€230.00
21.08.23
6.54%
04.09.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€214.90
21.08.22
€87.00
21.08.23
-3.44%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€91.50
10.08.21
-
10.08.22
-42.25%
10.08.22

buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€33.09
30.10.21
€45.00
31.12.23
94.65%
05.08.22

Could be very worthwhile Investment >20% year
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€152.65
16.11.21
€200.00
31.01.25
36.59%
03.08.22

Could be worthwhile Investment >10% per year
buy
Repligen Corp.

Start price
Target price
Perf. (%)
€210.00
03.08.21
-
03.08.22
13.21%
03.08.22

buy
Repligen Corp.

Start price
Target price
Perf. (%)
€174.95
08.07.21
-
08.07.22
-2.46%
08.07.22

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€38.17
08.07.21
-
08.07.22
30.25%
08.07.22

buy
Bio-Techne Corp.

Start price
Target price
Perf. (%)
€24.00
08.07.21
-
08.07.22
-7.29%
08.07.22

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€146.45
08.07.21
-
08.07.22
2.31%
08.07.22

Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€9.23
09.11.21
€7.00
31.12.23
-56.18%
28.06.22

Could be very worthwhile Investment >20% year
buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€2.81
30.05.22
-
30.05.23
23.85%
08.06.22

Risky Investment
buy
Arrowhead Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€54.60
08.07.21
-
08.07.22
-37.34%
21.05.22

buy
Ensign Group Inc.

Start price
Target price
Perf. (%)
€71.50
03.05.21
€78.00
03.05.22
2.80%
04.05.22

Could be worthwhile Investment >10% per year